HomeCompareRCOR vs KMB

RCOR vs KMB: Dividend Comparison 2026

RCOR yields 62.50% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RCOR wins by $690.1K in total portfolio value
10 years
RCOR
RCOR
● Live price
62.50%
Share price
$3.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$735.9K
Annual income
$177,443.13
Full RCOR calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — RCOR vs KMB

📍 RCOR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRCORKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RCOR + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RCOR pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RCOR
Annual income on $10K today (after 15% tax)
$5,312.50/yr
After 10yr DRIP, annual income (after tax)
$150,826.66/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, RCOR beats the other by $146,397.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RCOR + KMB for your $10,000?

RCOR: 50%KMB: 50%
100% KMB50/50100% RCOR
Portfolio after 10yr
$390.9K
Annual income
$91,327.22/yr
Blended yield
23.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

RCOR
Analyst Ratings
2
Buy
Consensus: Buy
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RCOR buys
0
KMB buys
0
No recent congressional trades found for RCOR or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRCORKMB
Forward yield62.50%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$735.9K$45.9K
Annual income after 10y$177,443.13$5,211.33
Total dividends collected$614.9K$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: RCOR vs KMB ($10,000, DRIP)

YearRCOR PortfolioRCOR Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$16,950$6,250.00$11,314$613.68+$5.6KRCOR
2$28,037$9,900.70$12,865$759.19+$15.2KRCOR
3$45,305$15,305.49$14,709$943.96+$30.6KRCOR
4$71,591$23,114.13$16,919$1,180.17+$54.7KRCOR
5$110,737$34,135.17$19,588$1,484.33+$91.1KRCOR
6$167,835$49,346.36$22,838$1,879.06+$145.0KRCOR
7$249,481$69,897.34$26,832$2,395.60+$222.6KRCOR
8$364,047$97,102.68$31,788$3,077.63+$332.3KRCOR
9$521,955$132,424.34$38,000$3,986.82+$484.0KRCOR
10$735,935$177,443.13$45,872$5,211.33+$690.1KRCOR

RCOR vs KMB: Complete Analysis 2026

RCORStock

Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.

Full RCOR Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this RCOR vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RCOR vs SCHDRCOR vs JEPIRCOR vs ORCOR vs KORCOR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.